Overview
Status
Active
Registry date
2012-10-26
Share capital
80,000.00 PLN
Registered address
Leszno 8/1, 01-192 Warszawa, Poland
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 200 days late).
- 202511/06/2026
- 202412/06/2025
- 202304/07/2024
- 202221/03/2023
- 202131/01/2023
- 202006/07/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations197 / 231
Top 85%
Results vs industry
Revenue
This companyUSD 16.83kMedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD -6.82kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 19.86kMedianUSD 873.06kAverageUSD 21.43m
Assets
This companyUSD 49.72kMedianUSD 897.46kAverageUSD 31.52m
Industry
Authorized Representatives
Henryk Gruza – President of the Management Board
Manner of representation
In the case of a one-person management board – one member of the management board independently. In the case of a multi-member management board – two members of the management board acting jointly.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Henryk Gruzaage 64 | 1,584 | $21,393.84 | 99% |
Others | 16 | $216.10 | 1% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2013-01-02.
25 1240 6175 1111 0010 4884 2407
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
Change history
| Date | Event | |
|---|---|---|
| 2015-07-28 | PKD change (Removed: 46.90.Z) | |
| 2012-12-31 | Share capital increase (5,000.00 PLN → 80,000.00 PLN) | |
| 2012-12-31 | Name change (Management Consulting → Fdfpharma) | |
| 2012-12-31 | PKD change (Removed: 36 codes; Added: 9 codes) | |
| 2012-10-26 | Entered in the register |
FAQ
The main business activity of Fdfpharma focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on October 26, 2012.
The headquarters is located at: Leszno 8, 01-192 Warszawa.
The share capital of the company is PLN 80,000 (approx. $21,610).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of $16,828 in 2025, which is a decrease of 13.8% compared to 2024.
No, in 2025 the company was not profitable, reporting a net loss of $6,822. For comparison, in 2024 the loss was $6,033, meaning the company increased its loss by 12.8%.
The largest operating cost category falls under external services. This category amounted to $12,756 in 2025, representing 64% of all operating expenses.
Last updated: 2026-06-11